| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Intelligent Bio Solutions Inc. Common Stock$2.21
-0.08 (-3.49%)
F 2Pipeline Score Tools & Services · Clinical
Market Cap
4.92 M
EPS
-14.93
P/E Ratio
-0.16 $
Value Trade
177.50 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.06 M
Total Assets
14.86 M
Total Liabilities
6.11 M
Equity
8.96 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
6.86 M
Monthly Burn
982.00 K
Runway
5 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
80.32 K
52 Week Range
2.46 - 24.90
% held by Insiders
3.78 %
% held by Institutions
8.71 %
Enterprise Value
5.90 M
Total Shares
1.60 M
Short %
3.7 %
Float Shares
1.59 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 877 of 912)
Percentile RankIntelligent Bio Solutions Inc. Common Stock has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INBS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INBS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-INBS
Jun 16, 2026Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
Intelligent Bio Solutions Inc. has initiated an Interference Study to support its FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System. This study, conducted in partnership with CenExel Clinical Research, aims to validate the system's accuracy in the presence of common substances. Results are expected by mid-July 2026 and will be included in the FDA submission package.
Read more →-INBS
Jun 2, 2026Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
Intelligent Bio Solutions Inc. has commenced a multi-site Method Comparison Study to support its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System. The study aims to validate the system's accuracy and performance in real-world workplace settings, involving 135 participants. Results will be included in the FDA submission package, expected by July 2026.
Read more →-INBS
May 13, 2026▲ +25.5%on this news
Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
Intelligent Bio Solutions Inc. reported a 46% increase in revenue for the fiscal third quarter, driven primarily by a 59% rise in cartridge sales. The company achieved a gross profit margin of 50.5%, reflecting enhanced operational efficiencies. With nine-month revenue reaching $3.07 million, INBS is well-positioned for growth as it approaches key FDA regulatory milestones.
Read more →-INBS
Apr 17, 2026Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified
Intelligent Bio Solutions Inc. has successfully completed penetration testing as part of its FDA 510(k) submission, identifying no major vulnerabilities. The company has also implemented security upgrades to enhance its drug testing technology. These developments are expected to strengthen its regulatory submission and open new revenue opportunities in the U.S. drug screening market.
Read more →-INBS
Mar 26, 2026Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant
Intelligent Bio Solutions Inc. has received its eighth European patent, enhancing its intellectual property portfolio related to fingerprint sweat drug testing technology. The new patent focuses on contextualizing chemical analysis with fingerprint deposition volume, improving the interpretation of test results. This advancement reinforces the company's market position and supports its innovative, non-invasive testing solutions.
Read more →-INBS
Feb 25, 2026Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
Intelligent Bio Solutions Inc. has successfully manufactured and shipped its first drug screening readers in collaboration with Syrma Johari, marking a significant step towards scaling production. The partnership is expected to yield over 40% in annual production cost savings and improve gross margins by approximately 20 percentage points. The company has also doubled its in-house production capacity for lateral flow test strips, enhancing its operational capabilities ahead of its planned U.S. market entry in 2026.
Read more →-INBS
Feb 24, 2026Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
Intelligent Bio Solutions Inc. has partnered with Bouygues UK to implement its fingerprint drug screening technology across 13 project sites in the UK. This collaboration marks a shift from third-party testing to an in-house solution, emphasizing hygiene, efficiency, and cost savings. The partnership is seen as a foundation for potential future expansions within Bouygues' global operations.
Read more →-INBS
Feb 12, 2026▼ -6.7%on this news
Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
Intelligent Bio Solutions Inc. reported a 48% increase in revenue for the fiscal second quarter of 2026, driven by a 104% surge in reader sales. The company achieved a gross profit margin of 49%, up from 39% the previous year. With total revenue exceeding $2 million in the first half of the fiscal year, INBS is building a sustainable business model focused on non-invasive drug testing solutions.
Read more →-INBS
Feb 5, 2026▼ -9.1%on this news· ran to -21% by day 3
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
Intelligent Bio Solutions Inc. anticipates a 48% revenue growth for fiscal Q2 2026, exceeding $2 million in total revenue for the first half of the fiscal year. The company reports significant growth in reader sales, expected to more than double year-over-year. This growth is attributed to an expanding customer base and a robust product offering, reinforcing their recurring revenue model.
Read more →-INBS
Jan 29, 2026Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market
Intelligent Bio Solutions Inc. has launched clinical studies to support its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System, aimed at detecting codeine. The studies will assess detection cut-off levels and are expected to conclude by March 2026. This initiative positions the company to enter the lucrative U.S. drug screening market, leveraging its non-invasive technology.
Read more →-INBS
Jan 5, 2026▲ +39.4%on this news· ran to +81% by day 3
Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Intelligent Bio Solutions Inc. has successfully closed a $10 million private placement with institutional investors, issuing approximately 2.3 million shares and associated warrants. The funds will be used for working capital, including a 510(k) submission to the FDA for their Intelligent Fingerprinting Drug Screening System. The company aims to expand its market presence internationally.
Read more →-INBS
Jan 1, 2026▼ -17.2%on this newsshared move
Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins
Intelligent Bio Solutions Inc. has announced a strategic partnership with Syrma Johari MedTech to enhance its manufacturing capabilities. This collaboration aims to improve gross margins by approximately 20 percentage points and significantly increase production capacity. The partnership is expected to bolster supply chain resilience as INBS prepares for its U.S. market entry in 2026.
Read more →-INBS
Jan 1, 2026▼ -17.2%on this newsshared move
Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Intelligent Bio Solutions Inc. has announced a private placement to raise approximately $10 million by issuing shares and warrants. The placement is priced at $4.35 per share and is expected to close on January 2, 2026. The proceeds will be used for working capital and general corporate purposes, with an agreement to file a registration statement with the SEC.
Read more →-INBS
Dec 12, 2025▼ -22.7%on this news
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
Intelligent Bio Solutions Inc. announced a 1-for-10 reverse stock split, effective December 15, 2025. This decision was approved by stockholders during an annual meeting on October 16, 2025. Following the split, each ten shares will be combined into one, maintaining the company’s par value at $0.01 per share and keeping the total authorized shares at 100 million. The move aims to adjust the stock's market price without altering stockholders' percentage interests.
Read more →-INBS
Nov 12, 2025Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28
Intelligent Bio Solutions Inc. reported a record revenue of $1.11 million for the first quarter of fiscal 2026, representing a 32% sequential increase. The growth was driven primarily by consumable cartridge sales, reflecting an expanding customer base as well as strategic partnerships. Gross profit margins also showed significant improvement, increasing to 46.6%. The company secured a major contract with a London public transport operator, further establishing its presence in international markets and diversifying its revenue streams.
Read more →-INBS
Nov 4, 2025▼ -9.1%on this news
Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year C ompany Achieves Third Consecutive Quarter of
Intelligent Bio Solutions Inc. anticipates reporting record revenue for the fiscal first quarter 2026, exceeding $1 million, marking a 32% sequential and 28% year-over-year increase. This achievement signifies the company's third consecutive quarter of revenue growth, driven by strong demand for its cartridge and reader sales. The business model's effectiveness appears reinforced by an increased sales mix of higher-margin consumables. Further financial details will be provided in the upcoming Quarterly Report on Form 10-Q.
Read more →-INBS
Oct 30, 2025▲ +8.3%on this newsshared move
Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480
Intelligent Bio Solutions Inc. (NASDAQ: INBS) reported the acquisition of 33 new customer accounts in fiscal Q1 2026, a 50% increase from the previous year, bringing total active accounts to 480. The company's growth is evident across multiple sectors, particularly in government administration, which is a new market for INBS. The firm's fingerprint-based drug testing technology is recognized for its operational benefits, particularly in enhancing compliance and minimizing downtime. With the global drug screening market expected to grow significantly, INBS is well-positioned for sustained revenue growth.
Read more →-INBS
Sep 26, 2025▼ -12.5%on this news
Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance The Company is initiating clinical studies to further validate Intelligent Fingerprinting
Intelligent Bio Solutions Inc. has provided an update regarding its plans for FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening System for codeine. The company is set to initiate clinical studies aimed at validating the technology, with completion expected in early 2026. An anticipated resubmission to the FDA is projected for the latter half of 2026. The ongoing efforts reflect the company's commitment to bringing innovative, non-invasive drug testing technology to the U.S. market amidst existing global adoption.
Read more →-INBS
Sep 17, 2025▼ -25%on this news
Intelligent Bio Solutions Provides Update on FDA 510(k) Clearance Process for Intelligent Fingerprinting Drug Screening System
Intelligent Bio Solutions Inc. has provided an update regarding its FDA 510(k) clearance for the Intelligent Fingerprinting Drug Screening System. The FDA issued an AI request consisting of over 70 items requiring clarification, prompting the company to submit additional information. Although the FDA is generally satisfied, the request for a resubmission means further delays are anticipated. Despite the challenges, INBS remains committed to the clearance process and continues to grow its market presence internationally.
Read more →-INBS
Aug 15, 2025Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies Company advanced efforts t
Intelligent Bio Solutions Inc. (INBS) reported robust financial growth in fiscal 2025, achieving a 16% increase in revenue year-on-year, attributed to heightened demand for its drug testing cartridges. The company is advancing its strategy for U.S. market expansion beyond forensic use, with ongoing efforts to secure FDA 510(k) clearance for its testing system. Global presence continues to strengthen, adding 115 new accounts and expanding into various international markets. Looking ahead, INBS prioritizes further growth and operational excellence.
Read more →-INBS
Aug 7, 2025Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum Company anticipates fiscal fourth quarter sequential an
Intelligent Bio Solutions Inc. released preliminary unaudited revenue results for the fiscal fourth quarter and full year ending June 30, 2025, expecting a 16% increase both sequentially and year-over-year. The company has made strides toward obtaining FDA 510(k) clearance for its opiate test system and enhanced its global operations through system upgrades and localized websites. With promising demand for its products, especially among workplace drug screening applications, the company is poised for a successful rollout. Detailed financial results will be disclosed in the upcoming Annual Report on Form 10-K.
Read more →-INBS
Aug 6, 2025Intelligent Bio Solutions Strengthens FDA 510(k) Package with New Cybersecurity and Performance Data Ahead of Planned U.S. Market Launch FDA response expected within six weeks; Company remains focused on 2025 U.S. expans
Intelligent Bio Solutions Inc. has reinforced its FDA 510(k) submission with new cybersecurity and performance data ahead of a planned U.S. market launch. The submission includes significant testing results, demonstrating the technology's reliability and security. With a response from the FDA expected in six weeks, the company is optimistic about entering the multi-billion-dollar U.S. market by 2025. The company is actively expanding its presence internationally while prioritizing FDA clearance for its unique fingerprint sweat-based drug screening technology.
Read more →-INBS
Jul 25, 2025▼ -15.3%on this news
Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds Proceeds to Fund Completion of the Company's 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System
Intelligent Bio Solutions Inc. has entered into agreements to raise approximately $3.8 million through the exercise of existing warrants at a reduced price. The funds are intended to support the completion of the company's 510k filing with the U.S. FDA for their innovative Fingerprint Drug Screening System. This system aims to provide rapid, non-invasive drug testing, potentially addressing significant workplace safety needs. The transaction is expected to close by July 28, 2025, pending customary conditions.
Read more →-INBS
Jul 23, 2025▼ -5.8%on this news· ran to -32% by day 3shared move
Intelligent Bio Solutions to Strengthen FDA 510(k) Submission with New Positive Data Demonstrating Ultra-Precise Fingerprint Sweat Detection and Platform Resilience Data confirms Company's ability to detect trace sweat v
Intelligent Bio Solutions Inc. has announced the successful collection of new data that enhances the security and performance of its Intelligent Fingerprinting Drug Screening System. This development strengthens the company's ongoing FDA 510(k) submission process, with plans to submit findings in August. The company has invested significant resources into testing and refining its technology, which aims to detect common drugs through fingerprint sweat analysis. As it prepares for its market entry in the U.S. in 2025, the company is positioned robustly compared to previous stages of development.
Read more →-INBS
Jul 16, 2025▲ +12.1%on this news
Intelligent Bio Solutions Accelerates Global Growth with SmarTest Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority
Intelligent Bio Solutions Inc. (INBS) has entered a global distribution agreement with SMARTOX to offer its SmarTest Patch drug detection product internationally. This collaboration builds on their existing partnership, allowing INBS to enhance its position in the non-invasive drug testing market. The introduction of the SmarTest Patch is expected to create new opportunities in sectors like justice and rehabilitation, aligning with the growing global drug testing market. Additionally, INBS is prioritizing FDA approval for its technology for broader applications in the U.S.
Read more →-INBS
Jul 15, 2025▲ +9.8%on this news· ran to +24% by day 3shared move
Intelligent Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing
Intelligent Bio Solutions Inc. (INBS) has launched the SmarTest Patch, a next-generation wearable device for continuous non-invasive drug detection via sweat. This device complements the company's existing Intelligent Fingerprinting Drug Testing Solution, providing a range of detection options over 7-10 days. The introduction of the SmarTest Patch aims to strengthen INBS's position in the non-invasive testing market, particularly in sectors like justice and rehabilitation. The update implies an expansion of their product portfolio, enhancing flexibility and choice for customers in various industries.
Read more →-INBS
May 15, 2025Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges
Intelligent Bio Solutions Inc. (INBS) reported significant growth, reaching over 450 active accounts in 24 countries, driven by high demand for its Intelligent Fingerprinting Drug Screening System. This device allows for quick, non-invasive drug testing through fingerprint sweat analysis, capable of delivering results in under ten minutes. The company has successfully expanded its services into new regions and industries, including luxury marine and e-commerce, while enhancing its global distributor network. These developments are paving the way for INBS's entry into the lucrative U.S. market.
Read more →-INBS
May 13, 2025▲ +11.5%on this newsshared move
Intelligent Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements 20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued m
Intelligent Bio Solutions Inc. reported its financial results for the fiscal third quarter ending March 31, 2025, showcasing significant growth with a 20% increase in quarterly revenue and a remarkable 91% year-over-year rise in gross profit. The company attributed its success to the rising sales of higher-margin cartridge products, which now compose 58% of total revenue. The quarter also saw the addition of 35 new customers, contributing to a robust active account base of over 450. Efforts to expand internationally and enhance product accessibility through multilingual upgrades were highlighted as key strategies for sustained growth.
Read more →-INBS
Mar 26, 2025▼ -5.1%on this news· ran to -18% by day 3
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry Company's 6 th U.S. patent adds to comprehensive IP portfolio protecting its unique drug scr
Intelligent Bio Solutions Inc. has announced the granting of its sixth U.S. patent related to its Intelligent Fingerprinting Drug Screening Cartridge, aimed at strengthening its intellectual property portfolio as it plans to enter the U.S. market in 2025. This patent covers a fundamental aspect of the company's testing system which utilizes lateral flow technology to detect drugs in fingerprint sweat. The grant of this patent enhances the company's competitive position in the multi-billion dollar drug screening market and addresses the increasing demand for safe work environments in various industries. The company also highlights its commitment to innovation in drug screening technology, which promises rapid, non-invasive testing solutions.
Read more →-INBS
Mar 25, 2025▼ -16.6%on this news· ran to -28% by day 3shared move
Intelligent Bio Solutions' FDA Clearance Process Remains on Track for 2025 U.S. Launch
Intelligent Bio Solutions Inc. (INBS) has provided an update on its FDA clearance process for the Intelligent Fingerprint Drug Screening System, which is slated for a 2025 U.S. launch focusing on opiate detection. The company submitted its 510(k) premarket notification, which included performance data showing a 94.1% accuracy. However, the FDA's review may extend beyond the typical 90-day period due to the issuance of an Additional Information request. Despite these potential delays, the company is preparing for its market entry and considering further FDA submissions for additional drug classes.
Read more →-INBS
Mar 20, 2025Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced the expected grant of its sixth patent in the U.S., which will bolster its intellectual property regarding non-invasive drug testing technology. The pending patent is part of a strategy to enhance their market position and support their entry into the U.S. drug screening market in 2025. The company believes that its innovative sweat-based testing approach will significantly benefit industries prioritizing workplace safety. However, there are inherent risks associated with the commercialization of its drug and diagnostic tests.
Read more →-INBS
Feb 19, 2025▲ +6.5%on this news
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
Intelligent Bio Solutions Inc. has announced a proposed underwritten public offering of its common stock as part of its strategy to raise capital. The offering is contingent upon market conditions and does not guarantee size or completion. The company, known for its rapid, non-invasive testing solutions, has filed necessary documents with the SEC and aims to leverage its innovative technologies for growth. However, there are uncertainties surrounding the actual execution and potential risks associated with forward-looking statements made by the company.
Read more →-INBS
Feb 13, 2025Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submi
Intelligent Bio Solutions Inc. reported a strong fiscal Q2 2025, highlighting a 32.6% increase in gross profit and improved profit margins. The company is on track for expansion into the U.S. market after successfully submitting its FDA 510(k) package. Despite a decrease in overall sales revenue, the company is focusing on higher-margin cartridge sales and has made strategic partnerships for growth in international markets. The announcement reflects both operational success and ongoing investments in research and development.
Read more →-INBS
Feb 10, 2025Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 202
Intelligent Bio Solutions Inc. (INBS) has released a shareholder letter outlining its successes in 2024 and plans for U.S. expansion in 2025. The company achieved a 148% increase in revenue and is positioned to enter the U.S. drug screening market following its 510(k) FDA submission. As rising positivity rates for drug use are observed, INBS anticipates growing demand for its non-invasive drug testing solutions. The letter highlights both the significant milestones reached and the potential challenges the company may face as it implements its strategy to capture market share.
Read more →-INBS
Feb 7, 2025▲ +8.7%on this news· ran to +28% by day 3shared move
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch Avon Freight Group selects INBS' fingerprint drug testing for three UK sites, reinforcing workplace safety and eff
Intelligent Bio Solutions Inc. (INBS) has announced a partnership with Avon Freight Group for its fingerprint drug testing solution across three UK sites. This move is intended to enhance workplace safety and maintain employee well-being. INBS has surpassed 400 accounts in 19 countries and is preparing for its U.S. launch in 2025 after submitting an application to the FDA. The UK drug testing market's projected growth further solidifies INBS' position in the industry.
Read more →-INBS
Feb 6, 2025▲ +14.7%on this news· ran to +25% by day 1shared move
Intelligent Bio Solutions Expects to Achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fi
Intelligent Bio Solutions Inc. (INBS) announced its unaudited financial results for the fiscal second quarter and six months ended December 31, 2024, reporting a gross profit increase of 32.6%. The Company achieved revenues of approximately $0.61 million for the quarter and $1.48 million for the six months, driven by higher-margin cartridge sales. Additionally, INBS submitted its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, which positions the Company for market entry in the competitive U.S. drug screening sector. Strategic partnerships are expected to expand the Company’s reach and brand awareness.
Read more →-INBS
Jan 31, 2025▲ +11.4%on this news
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade Multilingual upgrade will make INBS' Drug Screening System accessible to over 4 billion users worldwide, includ
Intelligent Bio Solutions Inc. (INBS) has announced a significant upgrade to its Intelligent Fingerprinting Drug Screening System, which will now support multiple languages. This enhancement aims to improve accessibility for over 4 billion users globally, catering to diverse customer needs across various regions including the Americas, Europe, Asia, and the Middle East. The upgrade is a key step in INBS's strategic objective of entering the US market in 2025 and capitalizing on the projected growth in the workplace drug testing sector, estimated to reach $8 billion by 2030.
Read more →-INBS
Jan 29, 2025Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-h
Intelligent Bio Solutions Inc. has added Quantum Traffic Management to its portfolio, enhancing its offerings with a non-invasive fingerprint drug testing solution. This transition from traditional saliva and urine testing to the Intelligent Fingerprinting Drug Testing System seeks to improve workplace testing efficiency across Quantum TM’s nationwide sites in the UK. With more than 400 accounts globally, INBS is also looking to enter the US market in 2025, following a recent FDA 510(k) submission. The innovative technology aims to generate on-the-spot drug screening results, benefitting industries where rapid testing is critical.
Read more →-INBS
Jan 28, 2025Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe's $3.6 Billion Drug Screening Market and in Middle Eastern Regions
Intelligent Bio Solutions Inc. (INBS) has partnered with IVY Diagnostics to strengthen its foothold in the growing drug screening markets of Europe and the Middle East. This collaboration is aimed at expanding the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution, focusing primarily on applications in drug rehabilitation and law enforcement. Given the projected growth of the drug screening markets, INBS is poised to capture new opportunities. IVY Diagnostics will facilitate this expansion through its extensive network and expertise in regulatory landscapes.
Read more →-INBS
Dec 18, 2024▼ -8.3%on this news
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
Intelligent Bio Solutions Inc. has announced the submission of its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System. This innovative technology, which offers a rapid and non-invasive method for drug testing through fingerprint sweat analysis, achieved a notable accuracy of 94.1% in validation studies. The company's entry into the US market is anticipated in 2025, aiming to capitalize on a substantial market for drug screenings. The system is designed to meet the demands of various sectors, including law enforcement and safety-critical industries.
Read more →-INBS
Nov 26, 2024▲ +6.6%on this news
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth
Intelligent Bio Solutions Inc. recently completed a method comparison study on its Intelligent Fingerprinting Drug Screening System, achieving 94.1% accuracy. The study confirms the system's reliability and usability for drug testing, and follows positive results from an earlier pharmacokinetic study. The company plans to submit data from both studies to the FDA for 510(k) clearance, expected in the fourth quarter of 2024. This development signifies a key milestone towards introducing the non-invasive drug testing technology to the US market.
Read more →-INBS
Nov 13, 2024▼ -12.4%on this news· ran to -27% by day 3
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA
Intelligent Bio Solutions Inc. announced positive results from its Pharmacokinetic (PK) study, which is a critical step toward obtaining FDA 510(k) clearance. The study indicates that fingerprint sweat accurately reflects the presence of codeine, suggesting its reliability as a non-invasive sample for drug detection. The company plans to submit this and other relevant clinical data for regulatory review in the fourth quarter of the current year, aiming for a market introduction of their testing technology in the U.S. by 2025. The results highlight the potential applicability of this technology in various sectors, including law enforcement and safety-critical industries.
Read more →-INBS
Nov 7, 2024▲ +13.2%on this news· ran to +28% by day 3
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-
Intelligent Bio Solutions Inc. reported a positive financial performance for the first quarter of fiscal 2025, with a 10% increase in revenue year-on-year and a significant 20% increase compared to the previous quarter. The company also highlighted that its cartridge sales have overtaken reader revenue, which is a positive shift for its business margins. Operationally, the firm is on track to submit its FDA 510(k) package by year-end, aiming to capitalize on a growing drug screening market. Despite these positives, the company faces challenges with rising net losses due to ongoing investments in research and development.
Read more →-INBS
Oct 29, 2024Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge rev
Intelligent Bio Solutions Inc. has announced preliminary unaudited revenue results for Q1 of fiscal 2025, reporting approximately $0.87 million in revenue. This reflects a 10% increase compared to the same period last year and a 20% increase from the previous quarter. The company anticipates a shift towards higher-margin revenue from cartridge sales, which are expected to outpace reader sales. Additionally, the firm is focusing on expanding its distribution network in Saudi Arabia to meet increasing demand for its drug testing solutions.
Read more →-INBS
Sep 27, 2024Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(k) Submission. New York
Intelligent Bio Solutions Inc. has successfully concluded in-clinic testing as part of its clinical study plan aimed at FDA 510(k) submission. The testing evaluated the accuracy of the company's innovative sweat-based drug screening method. Clinical data analysis is expected to be completed by the end of 2024, with the 510(k) package planned for submission during the same quarter. This progress is seen as a significant step toward the commercialization of a non-invasive alternative to traditional drug testing methods.
Read more →-INBS
Sep 19, 2024▼ -18%on this news
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights - Fourth-quarter revenue of $0.73 million, up 64% year-over-year - - Full-year revenue of $3.11
Intelligent Bio Solutions Inc. reported strong financial results for the fiscal year ended June 30, 2024, with fourth-quarter revenue rising by 64%, totalling $0.73 million. The full-year revenue reached $3.11 million, a significant increase of 148% compared to the prior year. The company has continued to expand its presence with strategic partnerships and product launches, including expansions into the APAC region and Europe. However, it reported a net loss of $10.16 million for the year, although this was an improvement from the previous year's losses.
Read more →-INBS
Sep 9, 2024▲ +13.3%on this news
Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year - 2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% y
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced preliminary unaudited revenue growth of 148% year-over-year for the fiscal year ended June 30, 2024, with Q4 revenues increasing by 64%. The company cited rising market demand and increased brand awareness as key drivers of growth, alongside a growing customer base. INBS is positioning itself within safety-critical sectors such as construction and logistics, where non-invasive drug testing solutions are increasingly needed. The company anticipates continued growth as it expands its reach into new markets and industries.
Read more →-INBS
Sep 5, 2024Intelligent Bio Solutions Inc. Announces Progress Toward Completion of Clinical Study Plan Required for FDA 510(k) Submission
Intelligent Bio Solutions Inc. has announced notable progress towards completing the clinical study plan needed for its FDA 510(k) submission. The company is collaborating with CenExel to perform method comparison studies involving 135 healthy adult subjects. Currently, about one-third of the enrollment targets have been met, and the in-clinic portion of a pharmacokinetic study has been finished, with analysis of the data ongoing. The company aims to submit to the FDA in the fourth quarter of 2024, showcasing the effectiveness of its Intelligent Fingerprinting Drug Screening System.
Read more →-INBS
Sep 3, 2024▼ -5.7%on this newsshared move
Intelligent Bio Solutions Inc. Reports 118% Year-Over-Year Growth in Customer Employee Base, Reaching an Estimated Total of 1.4 Million Employees
Intelligent Bio Solutions Inc. (INBS) reported a substantial 118% year-over-year increase in its customer employee base, totaling approximately 1.4 million employees. The company attributes this growth to the rising adoption of its non-invasive drug testing technology, particularly among industries where occupational safety is critical. The average number of employees per new customer has also more than doubled compared to the previous fiscal year. CEO Simeonidis emphasized the importance of ensuring workers are fit for duty to enhance workplace safety.
Read more →-INBS
Aug 21, 2024▲ +9.7%on this news
Intelligent Bio Solutions Inc. Achieves Major Milestone with Over 1,000 Installed Intelligent Fingerprinting Drug Screening Readers as of
Intelligent Bio Solutions Inc. has announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers as of June 30, 2024, highlighting significant growth in demand for its drug testing technology. The company reported a 26% increase in reader sales year-over-year and a 20% increase in cartridge sales, establishing a robust ongoing revenue stream. With plans for FDA clearance and expansion into international markets, INBS aims to enhance its position in non-invasive drug testing. This milestone underscores the company's commitment to addressing workplace drug use issues.
Read more →-INBS
Aug 13, 2024Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries New York
Intelligent Bio Solutions Inc. (NASDAQ: INBS) has announced an increasing demand for drug testing solutions across several industries, including construction, transportation, and manufacturing. Highlighting alarming statistics on drug use among workers, the company emphasizes the significance of maintaining safety and productivity in the workplace. The firm is optimistic about its non-invasive Intelligent Fingerprinting Drug Screening System, which aims to provide effective and efficient testing methods. Additionally, Intelligent Bio Solutions plans to expand into new markets and discuss insights leading up to its upcoming Annual Report.
Read more →-INBS
Aug 1, 2024▼ -5.5%on this news
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
Intelligent Bio Solutions Inc. has announced a partnership with CenExel to conduct a critical method comparison clinical study as part of its FDA 510(k) submission plan. The study will involve 135 healthy adult subjects to compare results from their fingerprint sweat opiate screening technology against a validated LC-MS/MS method. This partnership and study are crucial steps in their product development, with the aim of submitting for FDA approval by the fourth quarter of 2024. The company's innovative technology is designed for rapid, non-invasive drug testing, offering significant potential for various industries.
Read more →-INBS
Jul 24, 2024Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia New York
Intelligent Bio Solutions Inc. has appointed QabasTech as its exclusive distributor in Saudi Arabia, aiming to expand its market presence. This collaboration supports INBS's objectives to enhance public safety through innovative drug screening solutions. Given the Saudi government's crackdown on drugs, the partnership is timely and aligns with the local market's demand for effective drug testing methods. The Intelligent Fingerprinting Drug Screening System promises to offer rapid results, catering to various sectors including government and drug rehabilitation centers.
Read more →-INBS
Jul 18, 2024▼ -12.3%on this news
Intelligent Bio Solutions Inc. Advances on FDA 510(k) Pathway with Biocompatibility Study Success NEW YORK, 18 July, 2024 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology co
Intelligent Bio Solutions Inc. has successfully completed its biocompatibility study for the Intelligent Fingerprinting Drug Screening System, a crucial step in the FDA 510(k) regulatory process. This study, conducted under ISO 10993 standards, confirms the safety of the system's materials for human use. The company aims to submit the 510(k) application in Q4 2024, targeting a market launch in 2025. With this milestone, INBS is advancing its innovative technology towards potential applications across various industries, especially in non-invasive drug testing.
Read more →-INBS
Jun 28, 2024Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results New York
Intelligent Bio Solutions Inc. has successfully completed the in-clinic portion of its pharmacokinetic (PK) study, which is part of its 510(k) regulatory pathway. This study aims to demonstrate the effectiveness of the company's fingerprint sweat collection method for drug testing, comparing the results with traditional specimen types such as blood and saliva. The company is now focused on analyzing the results and expects to complete the full PK study in the third calendar quarter of 2024.
Read more →-INBS
Jun 18, 2024Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology Pharmacokinetic study is key step on path to expansion i
Intelligent Bio Solutions Inc. (INBS) has initiated the dosing and sampling phase of its Pharmacokinetic (PK) Study as part of its 510(k) submission to the FDA. This study is crucial for demonstrating the safety and efficacy of its fingerprint drug screening technology, aiming for FDA clearance in the fourth quarter of 2024. With a focus on analyzing drug metabolism through fingerprint sweat samples, the company anticipates completing participant dosing by the end of June 2024, with results expected by the end of July 2024. Successful FDA approval could enable INBS to tap into the large US market in the first half of 2025.
Read more →-INBS
May 29, 2024Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study
Intelligent Bio Solutions Inc. has completed recruitment and begun subject screening for its pharmacokinetic study as part of the FDA 510(k) regulatory pathway. This study aims to analyze opiate metabolism using human sweat specimens, which will be compared with results from other matrices. The company's Intelligent Fingerprinting Drug Screening System is designed to provide rapid and non-invasive drug testing, offering potential applications across various industries. The completion of subject screening is anticipated in June 2024.
Read more →-INBS
May 23, 2024Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Soluti
Intelligent Bio Solutions Inc. (INBS) announced significant growth indicators from its UK operations, highlighting a 193% year-over-year revenue increase, largely driven by innovative, non-invasive drug testing solutions. The company has expanded its client base to over 400 customers across various industries. Amid rising drug test cheating rates, INBS's solutions are gaining traction, suggesting potential for similar success in the US market with an upcoming FDA submission. However, reliance on the UK for the majority of revenue presents certain risks.
Read more →-INBS
May 17, 2024▼ -5.5%on this news
Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event
Intelligent Bio Solutions Inc. showcased its Intelligent Fingerprinting Drug Screening Solution at the Health & Safety Event 2024 in the UK, attracting significant attention from over 11,500 attendees. The event highlighted the company's commitment to enhancing workplace safety and compliance through its technology. Discussions with prominent clients and a South American distributor marked the potential for future expansion. The solution's rapid, non-invasive testing method aims to revolutionize drug screening in various industries.
Read more →-INBS
May 8, 2024▼ -13.5%on this news
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months
Intelligent Bio Solutions Inc. reported financial results for the third quarter and nine months ended March 31, 2024, showcasing a robust revenue growth of 80% and 193%, respectively. The company's cash and cash equivalents rose significantly to $9.40 million, bolstered by a recent capital injection. With a strategic partnership for FDA clinical studies underway and the acquisition of 26 new customer accounts, the company is poised for future expansion. However, a net loss of $2.98 million and goodwill impairment charges present challenges that could influence its financial outlook.
Read more →-INBS
Apr 11, 2024Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader
Intelligent Bio Solutions Inc. has expanded its intellectual property portfolio by securing a new European patent for its DSR-Plus Cartridge Reader, following successful protection in the UK. The patented technology enables rapid drug screening through fingerprint sweat analysis, catering to safety-critical industries. The move signifies the company's commitment to its global expansion and enhancing workplace safety. The DSR-Plus Reader is designed for quick sample collection and result delivery, marking a significant advancement in drug testing methods.
Read more →-INBS
Mar 31, 2024Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months
Intelligent Bio Solutions Inc. reported preliminary unaudited revenue results for its fiscal third quarter and nine months ending March 31, 2024. The company achieved an 80% increase in quarterly revenue year-over-year, totaling approximately $0.82 million, and a remarkable 193% increase for the nine months, reaching about $2.38 million. The growth is attributed to the successful performance of its Intelligent Fingerprinting Drug Screening Solution, which is seeing heightened demand among businesses adopting stricter drug policies. The company will provide more detailed financial results in its upcoming Quarterly Report on Form 10-Q, expected by May 6, 2024.
Read more →-INBS
Mar 11, 2024Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Intelligent Bio Solutions Inc. has announced a private placement of $10.1 million, with plans to issue 2,223,333 shares of common stock and associated warrants. The pricing was set at $4.55 per share under Nasdaq rules, and the closing is expected on March 12, 2024, pending customary conditions. Proceeds from this offering are intended for working capital and general corporate purposes, which could enhance the company's operational capabilities. This strategic move reflects the company's commitment to advancing its non-invasive testing technologies.
Read more →-INBS
Feb 28, 2024Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
Intelligent Bio Solutions Inc. (INBS) has partnered with Cliantha Research to conduct a pharmacokinetic study as part of its FDA 510(k) pathway. The study will assess the presence of opiates in fingerprint sweat compared to traditional testing methods. This initiative represents a critical milestone for INBS as it seeks to validate its non-invasive testing technology. The clinical study will begin with subject recruitment planned for March and April 2024, with analysis expected to conclude by the end of June 2024.
Read more →-INBS
Feb 16, 2024▼ -9.2%on this news
Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders' Equity Requirement
Intelligent Bio Solutions Inc. (INBS) has announced that it has regained compliance with Nasdaq's Minimum Bid Price Requirement as of February 13, 2024, after the company's stock price remained above $1.00 for 11 consecutive business days. Additionally, the company confirmed compliance with the Nasdaq Stockholders' Equity Requirement, maintaining a minimum of $2.5 million in equity following its recent quarterly report. These developments are critical for INBS to continue its listing on the Nasdaq exchange.
Read more →-INBS
Feb 9, 2024▲ +134.9%on this news
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights - Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months en
Intelligent Bio Solutions Inc. (INBS) reported strong fiscal second quarter and six-month financial results, showcasing a remarkable revenue growth of 114% in Q2 and 337% year-over-year for the six-month period ending December 31, 2023. The company successfully expanded into the New Zealand market and increased its customer portfolio, including notable entities in the construction and marine sectors. Despite the impressive revenue figures, the company faced a significant increase in losses attributed to operations post-acquisition, alongside a reduction in cash reserves. The overall results reflect a commitment to growth and an expanding global presence in the drug screening market.
Read more →-INBS
Feb 5, 2024▼ -38.8%on this news· ran to -52% by day 3
Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds
Intelligent Bio Solutions Inc. has announced the exercise of existing Series E Warrants, achieving approximately $1.77 million in gross proceeds. These proceeds will be directed towards working capital and corporate purposes. The company plans to issue new Replacement Warrants, further engaging investors and extending their market presence. This development highlights the firm's ongoing commitment to innovate in non-invasive testing solutions, aimed at various industries.
Read more →-INBS
Feb 2, 2024▲ +146.9%on this newsshared move
Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results - Year-over-year unaudited revenue increased 114% for the fiscal second quarter and 337% for the six mont
Intelligent Bio Solutions Inc. has announced preliminary unaudited revenue results indicating a significant year-over-year increase of 337% for the six months ended December 31, 2023. The company expects approximately $1.56 million in revenue for this period, with a 114% increase for the fiscal second quarter. Growth has been attributed to the effectiveness of its drug screening solutions and expansion into new markets. The firm plans to further increase market penetration and expects continued growth through 2024.
Read more →-INBS
Jan 29, 2024▲ +19.1%on this news
Leading UK Timber Processor and Packaging Manufacturer, James Jones & Sons Ltd., Adopts Intelligent Bio Solutions' Fingerprint Drug Screening System Across its 25 Sites and 1,300 Employees Intelligent Fingerprinting to b
Intelligent Bio Solutions Inc. has announced that James Jones & Sons Ltd., a UK timber processor, will implement its Intelligent Fingerprinting Drug Screening System across 25 sites for its 1,300 employees. The system allows for non-invasive testing through fingerprint sweat analysis, which provides on-site results for multiple drug groups within ten minutes. This initiative supports the company's new substance misuse policy, highlighting its commitment to employee safety and well-being. The rollout includes 11 readers strategically deployed to cover both urban and remote locations, showcasing the flexibility of the testing solution.
Read more →-INBS
Dec 19, 2023▲ +33.3%on this news
Intelligent Bio Solutions Receives NATA Accreditation for its Revolutionary Fingerprint Sweat Drug Screening System
Intelligent Bio Solutions Inc. (INBS) has attained NATA accreditation for its Intelligent Fingerprinting Drug Screening Solution. This accreditation validates the company's commitment to high-quality product standards and opens opportunities for growth in various markets. The Fingerprint Sweat Drug Screening System provides a rapid and non-invasive method for drug testing, making it particularly beneficial for industries with strict testing policies. This achievement positions INBS as a trusted partner in compliance and safety across the Asia-Pacific region and beyond.
Read more →-INBS
Dec 18, 2023Pro Forma Balance Sheet
The pro forma balance sheet for Intelligent Bio Solutions Inc. as of October 31, 2023, shows a substantial increase in total assets, growing from $8.7 million in September 2023 to $10.12 million. Current assets, cash reserves, and shareholders' equity have all improved significantly, suggesting a period of growth for the company. However, the company's accumulated deficit grew, highlighting potential ongoing financial challenges despite the positive asset developments.
Read more →-INBS
Nov 8, 2023▲ +8.6%on this news· ran to +150% by day 3
Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights - First fiscal quarter revenue and government support income increased 191% year-over-year and 88% sequentiall
Intelligent Bio Solutions Inc. (INBS) announced strong financial results for its fiscal first quarter ending September 30, 2023, with revenue increasing by 191% year-over-year. The company has successfully expanded into new markets, including South America and New Zealand, and is advancing its plans to enter the U.S. market. Despite the growth, the company reported a net loss of $2.4 million, indicating ongoing financial challenges.
Read more →-INBS
Oct 5, 2023▼ -11.1%on this news
Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client VKVP Haulage adopts Fingerprint Drug Screening System to help drive proactive drug
Intelligent Bio Solutions Inc. has announced the adoption of its Intelligent Fingerprinting Drug Screening System by VKVP Haulage, which will support proactive drug testing within its logistics operations. Additionally, the company revealed that Auctus Management Group has successfully completed 25,000 drug tests using the same system. The technology provides non-invasive testing options and rapid results, making it an appealing choice for industries such as transportation and logistics. These developments highlight the growing acceptance of fingerprint testing as a viable solution for workplace drug screening.
Read more →-INBS
Oct 2, 2023▼ -53.5%on this newsshared move
Intelligent Bio Solutions Inc. Announces Pricing of $4,000,000 Underwritten Public Offering
Intelligent Bio Solutions Inc. announced an underwritten public offering of approximately $4 million to enhance its capital. The offering consists of shares of common and preferred stock, along with associated warrants. The Company plans to use the proceeds for general corporate purposes. This move is expected to close by October 4, 2023, subject to customary conditions. The company highlights its innovative fingerprinting drug screening technology, aiming for wider applications in medical diagnostics.
Read more →-INBS
Sep 27, 2023Intelligent Bio Solutions Obtains ISO Recertification for its Intelligent Fingerprinting Drug Screening Business International certification adds to Quality Management Systems credentials for the medical device industry
Intelligent Bio Solutions Inc. (INBS) has successfully obtained recertification for its Intelligent Fingerprinting Drug Screening business under the ISO 13485:2016 quality management standard, which is essential for medical device manufacturers. Effective October 14, 2023, this certification underscores the company's commitment to adhering to global quality standards. Additionally, INBS is focused on expanding its sales efforts into North America and the Asia Pacific regions, leveraging the certification to enhance credibility in these markets. The Intelligent Fingerprinting Drug Screening System is designed for rapid, non-invasive drug detection, showing promise in various sectors.
Read more →-INBS
Sep 21, 2023Intelligent Bio Solutions Successfully Debuts Intelligent Fingerprinting Drug Screening Solution at the 2023 Workplace Health & Safety Show in Sydney, Australia
Intelligent Bio Solutions Inc. (INBS) announced the successful launch of its Intelligent Fingerprinting Drug Screening System at the 2023 Workplace Health & Safety Show in Sydney, Australia. This innovative, non-invasive drug testing technology allows for quick screening at workplaces, directly targeting impairments on the day of testing. The company received significant interest from industry decision-makers, highlighting a growing commitment to preventive workplace safety measures. The system has potential applications across various safety-critical sectors and addresses the need for a dignified alternative to traditional testing methods.
Read more →-INBS
Sep 8, 2023Intelligent Bio Solutions Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test New assays for ketamine and tramadol testing pass initial Intelligent Fingerprinting desig
Intelligent Bio Solutions Inc. has completed a critical development milestone that allows for the addition of ketamine and tramadol to its Intelligent Fingerprinting Drug Screening System. The new assays have passed the initial design phase and are now set for scale-up and transfer to manufacturing, paving the way for potential clinical trials. This advancement comes amidst rising concerns regarding the misuse of these substances, highlighting the ongoing need for efficient drug testing solutions. The Intelligent Fingerprinting system is designed to offer rapid, non-invasive testing for drug use in various settings.
Read more →-INBS
Aug 24, 2023Intelligent Bio Solutions Inc. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Operational Highlights - Combined full-year revenue and government support income increased 355% year-over-year - - Re
Intelligent Bio Solutions Inc. (INBS) announced its fiscal 2023 financial results, showcasing a remarkable 355% increase in revenue year-over-year, attributed to the acquisition of Intelligent Fingerprinting Limited and market expansion in Australia. The company received FDA guidance on a regulatory pathway for its Intelligent Fingerprinting Drug Screening Cartridge, which positions it for growth in the U.S. market. Despite these positive indicators, the company reported a rise in net losses due to impairment of goodwill, reflecting ongoing financial challenges. The company has successfully secured new customers and additional patents, laying groundwork for future advancements.
Read more →-INBS
Aug 1, 2023Intelligent Bio Solutions Secures 8 New Customers with a Combined Workforce of Over 10,000 Employees Two Months into Product Launch in Australia
Intelligent Bio Solutions Inc. has successfully secured 8 new customers in Australia, who collectively employ over 10,000 individuals, just two months after launching its Intelligent Fingerprinting Drug Screening System. The company’s expansion highlights a growing need for alternative, non-invasive drug screening solutions in safety-critical industries such as Mining, Aviation, and Agriculture. The innovative technology offers quick results, utilizing fingerprint sweat analysis to detect recent drug use. The CEO has expressed commitment to further growth and meeting the diverse screening needs of Australian businesses.
Read more →-INBS
Jul 6, 2023Intelligent Bio Solutions Signs South American Distribution Agreement with TSCOM for Fingerprint Drug Screening System and Secures First Order
Intelligent Bio Solutions Inc. has announced a distribution agreement with Chile-based TSCOM SPA for its Intelligent Fingerprinting Drug Screening System, aimed at enhancing product availability in South America. The partnership has already led to the company's first order from a local electrical distribution company. The fingerprint testing system presents a non-invasive alternative to traditional drug testing methods. Intelligent Bio Solutions aims to grow its market presence through this collaboration while providing ongoing support and training to TSCOM's clients.
Read more →-INBS
Jun 28, 2023Intelligent Bio Solutions Receives Guidance from U.S. FDA on a Regulatory Pathway for Expansion into the United States for its Intelligent Fingerprinting Drug Screening Cartridge - Company intends to submit 510(k) pre-ma
Intelligent Bio Solutions Inc. (INBS) has received guidance from the U.S. FDA regarding the regulatory classification of its Intelligent Fingerprinting Drug Screening Cartridge, determining it as a Class II device. This decision paves the way for the company to submit a 510(k) pre-market notification, facilitating its market entry into the United States. The technology allows for rapid and non-invasive drug testing using fingerprint sweat, which has shown to be effective in maintaining workplace safety. With a growing client base and potential applications in various sectors, the company aims to redefine drug testing standards in the U.S.
Read more →-INBS
Jun 20, 2023Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million Grant Funding received to date from the Australian Federal Government totals USD $3.25 million
Intelligent Bio Solutions Inc. (INBS) has secured a second progress payment of USD $1.43 million from a grant awarded in 2021 by the Australian Federal Government, accumulating a total of USD $3.25 million. This funding is part of a broader initiative to establish a state-of-the-art medical device manufacturing facility in Australia. The grant emphasizes the government's commitment to fostering high-tech medical solutions. INBS leverages the funds to enhance its capabilities, particularly in rapid, non-invasive testing technologies.
Read more →-INBS
May 16, 2023Intelligent Bio Solutions Plans to Add Fentanyl Testing as it Further Enhances its Fingerprint-Based Drug Screening Solution Lab-testing pathway to expand capabilities of proprietary drug test screening to detect potent
Intelligent Bio Solutions Inc. (INBS) announced its plans to enhance its drug screening capabilities by adding fentanyl testing to its proprietary fingerprint-based testing system. This initiative aims to address the ongoing opioid crisis in the U.S., which has seen significant losses and health impacts due to opioid overdoses. The non-invasive nature of the testing method is designed to provide quick and hygienic drug testing options. Additionally, the company sees this expansion as a potential market opportunity both domestically and internationally.
Read more →-INBS
May 11, 2023Intelligent Bio Solutions Inc. Reports Fiscal 2023 Third Quarter Financial Results and Operational Highlights - Combined revenue and government support income increased 199% year-over-year - - Sequential revenue growth o
Intelligent Bio Solutions Inc. announced its fiscal 2023 third quarter results, highlighting a 199% increase in combined revenue and government support income year-over-year. The company filed a 513(g) submission with the U.S. FDA for its Intelligent Fingerprinting Drug Screening Cartridge and was granted a U.K. patent for its DSR-Plus Cartridge Reader. The successful completion of Milestone 7 in their biosensor development marks a key advancement. Despite these achievements, the company reported a net loss of $6.34 million for the quarter, largely due to a non-cash impairment of goodwill.
Read more →-INBS
May 2, 2023Intelligent Bio Solutions Scales Reach Throughout Asia-Pacific Region with Addition of Sales Team in Australia, New Distribution Hub and Office Facility Company secures new distribution and office facility to scale distr
Intelligent Bio Solutions Inc. (INBS) has announced the expansion of its operations in the Asia-Pacific region by adding a sales team in Australia and securing a new distribution hub and office facility. This move aims to enhance the distribution of its Intelligent Fingerprinting Drug Screening System, designed to address the rising issue of substance abuse in the workplace. The newly recruited sales executives are expected to help INBS penetrate the Australian market, which presents significant growth opportunities due to substantial productivity losses associated with drug and alcohol abuse in workplaces. CEO Simeonidis highlighted the importance of workplace safety and the role of their technology in improving employee performance.
Read more →-INBS
Apr 26, 2023UK Food Processing Equipment Manufacturer Latest to Adopt Intelligent Bio Solutions' Portable Fingerprint Drug Testing Solution "Having experienced urine drug testing myself, I know it's not a pleasant experience for any
Intelligent Bio Solutions Inc. announced that UK food processing manufacturer Dodman Limited has adopted its Intelligent Fingerprinting Drug Screening System. This innovative, portable drug testing solution offers a non-invasive alternative to traditional urine tests. The system analyzes fingerprint sweat to provide rapid results, significantly enhancing workplace safety. Dodman's adoption reflects a commitment to proactive health and safety measures in the food manufacturing sector.
Read more →-INBS
Apr 18, 2023Intelligent Bio Solutions Secures UK Patent for Intelligent Fingerprinting DSR-Plus Cartridge Reader Company's 13 th patent granted strengthens protection for unique and proprietary Intelligent Fingerprinting point-of-ca
Intelligent Bio Solutions Inc. has announced the granting of a UK patent for its Intelligent Fingerprinting DSR-Plus Cartridge Reader, marking the company's 13th patent overall. This development enhances the protection of the company's proprietary drug screening technology, facilitating rapid and portable drug testing. The DSR-Plus system allows for fast sample collection and on-screen results, making it suitable for various organizations looking to improve workplace safety. The patent signifies the company's commitment to expanding its diagnostic solutions internationally.
Read more →-INBS
Mar 27, 2023A & F Sprinklers Selects Intelligent Bio Solutions' Latest DSR-Plus Screening Unit to Support its Random Drug Screening Program "Deploying the latest Intelligent Fingerprinting reader unit has helped our HR team to incre
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has announced that A & F Sprinklers, a leading UK fire protection firm, has selected its DSR-Plus screening unit to enhance its random drug testing program. The upgrade reportedly allows for a nearly threefold increase in testing productivity due to the speed of the fingerprint-based analysis. The technology's flexibility and non-intrusive nature are aspects underscoring its suitability for modern HR practices in drug screening. Intelligent Bio Solutions continues to expand its reach within the drug testing sector, focusing on safety-critical industries.
Read more →-INBS
Mar 13, 2023Intelligent Bio Solutions Inc. Selects HASTA Laboratory as Drug Testing Specialist in Australia New York, NY
Intelligent Bio Solutions Inc. has selected HASTA Laboratory as its preferred drug testing specialist in Australia. This partnership aims to support the company’s Intelligent Fingerprinting System, which can screen for drug use via fingerprint sweat analysis. The system provides quick results for common drugs such as opioids and THC, ensuring a fast and non-invasive testing approach for various industries. The collaboration is seen as a pivotal step in scaling the company's laboratory testing program in the Australian market.
Read more →-INBS
Mar 7, 2023Intelligent Bio Solutions Inc. Announces Proposed Public Offering
Intelligent Bio Solutions Inc. has announced a proposed underwritten public offering of shares and warrants to purchase its common stock. This offering is part of a strategy to enhance its capital base and support the development of its diagnostic technology. The company is known for its innovative biosensor platform and other testing solutions aimed at chronic disease management. While details about the size and terms of the offering remain subject to market conditions, the move suggests a proactive approach to funding its projects.
Read more →-INBS
Mar 1, 2023Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Listing Requirement New York, NY
Intelligent Bio Solutions Inc. has announced that it has regained compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share. The company achieved this compliance on February 24, 2023, after being notified of its non-compliance in March 2022. Intelligent Bio Solutions is known for its real-time testing solutions and has recently enhanced its capabilities with the acquisition of Intelligent Fingerprinting Limited. This reinstatement of compliance supports its operational stability in the market.
Read more →-INBS
Feb 16, 2023Intelligent Bio Solutions Inc. files FDA 513(g) regulatory submission for Intelligent Fingerprinting Drug Screening Cartridge - 513(g) submission will allow Intelligent Bio Solutions Inc. to determine the most suitable F
Intelligent Bio Solutions Inc. has submitted a 513(g) request to the FDA for its Intelligent Fingerprinting Drug Screening Cartridge. This submission is designed to establish a suitable regulatory pathway in the U.S. market, marking an important step in their expansion strategy. The cartridge tests for the presence of four drugs from fingerprint sweat and is intended to enhance workplace safety by providing a non-invasive testing method. The company emphasizes its commitment to addressing drug abuse challenges in various industries.
Read more →-INBS
Feb 15, 2023Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights - Second quarter total revenue and government support income increased over 100% year-over-year- - Government
Intelligent Bio Solutions Inc. reported strong financial results for its fiscal second quarter ended December 31, 2022, highlighting a year-over-year revenue increase exceeding 100%. Key operational milestones included the successful completion of Milestone 7, significantly enhancing the performance of their biosensor platform. Despite a net loss of $0.42 million, the company maintained a cash position of $2.9 million and announced partnerships with customers interested in its non-invasive testing solutions. Overall, the company appears to be well-positioned for future growth as it advances its development pipeline.
Read more →-INBS
Feb 7, 2023Intelligent Bio Solutions Inc. Announces Leading Food Industry Logistics Provider to Implement Fingerprint Drug Testing, Replacing Urine Testing Boughey Distribution switches to Intelligent Fingerprinting for its faster
Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced that Boughey Distribution, a leading food logistics provider in the UK, will implement its fingerprint drug testing system, replacing the traditional urine testing method. This change is aimed at enhancing the efficiency and non-invasiveness of the drug screening process. The fingerprint test allows for quicker and more hygienic in-house testing, supporting Boughey's random drug screening initiatives. HR Head Mark Batch emphasized the importance of maintaining a fit workforce, especially given the manual handling demands of their operations.
Read more →-INBS
Dec 22, 2022Intelligent Bio Solutions Inc. Announces Closing of Private Placement Offering
Bio Solutions Inc. Announces Closing of Private Placement Offering YORK, Dec. 22, 2022 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company"), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practition
Read more →-INBS
Dec 21, 2022Intelligent Bio Solutions Inc. Announces Cancellation of FY 2021 Annual Meeting of Stockholders Company Intends to Hold FY 2022 Annual Meeting in February 2023
Bio Solutions Inc. Announces Cancellation of FY 2021 Annual Meeting of Stockholders Intends to Hold FY 2022 Annual Meeting in February 2023 YORK, Dec. 21, 2022 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company"), today announced that its Board of Directors has canc
Read more →-INBS
Nov 9, 2022Intelligent Bio Solutions Inc. Reports First Quarter Ending
Bio Solutions Inc. Reports First Quarter Ending September 30, 2022, Preliminary Financial Results and Recent Business Highlights Acquired Intelligent Fingerprinting Limited and its proprietary drugs of abuse screening technology - Announced new additions to Board of Directors a
Read more →-INBS
Oct 26, 2022GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (INBS) and Announces Key Executive Appointments - Name change to more closely reflect firm's expanding portfolio of intelligent, efficient, conveni
Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (INBS) and Announces Key Executive Appointments change to more closely reflect firm's expanding portfolio of intelligent, efficient, convenient and practical noninvasive and drug testing technologies and produ
Read more →-INBS
Oct 4, 2022GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology
Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) - GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary h
Read more →-INBS
Aug 31, 2022GBS Inc. Reports Fourth Quarter and Full Year ended
Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquis
Read more →-INBS
Jun 16, 2022GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse - Intelligent Fingerprinting Limited's commercial-stage, revenue
Inc. Enters into Exclusivity Agreement for an Acquisition of Point of Care Diagnostic Screening Technology on Opioids and Drugs of Abuse - Intelligent Fingerprinting Limited's commercial-stage, revenue-generating platform technology would provide an expanded product upon which
Read more →-INBS
May 11, 2022GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval - - Finalizing site selectio
Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights Initiated prospective study to collect coincident samples of oral fluid blood following IRB approval - Finalizing site selection at the University of Newcastle campus for the high-tech manufactur
Read more →-INBS
Mar 31, 2022GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center The trial is single center, prospective study to collect coincident samples of oral fluid
Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose is expected to en
Read more →-INBS
Feb 10, 2022GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights - Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4
Inc. Reports Second Quarter 2022 Financial Results and Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding from Australian Government - $11.19 Million in Cash, Cash Equiva
Read more →-INBS
Dec 13, 2021GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test New York, NY
Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test York, NY, December 13, 2021 - GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health p
Read more →-INBS
Nov 30, 2021GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study New York, NY
Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study York, NY, November 30, 2021 - GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at poi
Read more →-INBS
Nov 22, 2021Life Science Biosensor Diagnostics Pty Ltd Statement in Relation to Recent Sale of Shares in GBS Inc Life Science Biosensor Diagnostics Pty Ltd (LSBD) is the owner and licensor of the Biosensor platform currently license
Life Science Biosensor Diagnostics Pty Ltd Statement in Relation to Recent Sale of Shares in GBS Inc Life Science Biosensor Diagnostics Pty Ltd (LSBD) is the owner and licensor of the Biosensor platform currently licensed to GBS Inc and other corporations globally. The objecti
Read more →-INBS
Nov 11, 2021GBS Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test - Clinical Validation Study Results for SARS CoV2 Ab Test - Evaluating site locations for build out of high-tech man
Read more →-INBS
Nov 1, 2021GBS Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing New York, New York
Inc. Announces Executive Leadership Changes to Accelerate Product Development and Manufacturing York, New York November 1, 2021 GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practition
Read more →-INBS
Oct 13, 2021GBS Inc. Announces its Pre-Submission package is with the FDA New York, New York
Inc. Announces its Pre-Submission package is with the FDA York, New York October 13, 2021 GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced
Read more →-INBS
Aug 11, 2021GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights - Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facilit
Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility - Signs Strategic Partnerships with Johns Hopkins University,
Read more →Competitive Position
How INBS ranks across every disease it competes inCompetitive Position is a premium feature
See how INBS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial